Company performance
Add to research
Current Price
as of Jun 18, 2025$10.00
P/E Ratio
N/A
Market Cap
$253.14M
Description
Add to research
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA.
Metrics
Add to research
Overview
- HQWatertown, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerSELB
- Price$10+2.15%
Trading Information
- Market cap$253.14M
- Float32.02%
- Average Daily Volume (1m)65,348
- Average Daily Volume (3m)86,816
- EPS-$4.48
Company
- Revenue$38.91M
- Rev growth (1yr)-81.16%
- Net income-$17.71M
- Gross marginN/A
- EBITDA marginN/A
- EBITDAN/A
- EV$175.03M
- EV/Revenue4.50
- P/EN/A
- P/S6.66
- P/BN/A
- Debt/EquityN/A
Documents
Add to research
SEC Filings
Factset Street Account